Metsera (NASDAQ:MTSR) Stock Price Down 4% – Should You Sell?

Shares of Metsera, Inc. (NASDAQ:MTSR) were down 4% on Thursday . The company traded as low as $28.20 and last traded at $28.68. Approximately 22,857 shares changed hands during trading, a decline of 96% from the average daily volume of 566,749 shares. The stock had previously closed at $29.86.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on MTSR shares. Guggenheim started coverage on shares of Metsera in a research note on Tuesday, February 25th. They set a “buy” rating and a $56.00 target price on the stock. Evercore ISI began coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued an “outperform” rating on the stock. Cantor Fitzgerald started coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued an “overweight” rating on the stock. Finally, Bank of America started coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $38.00 target price on the stock.

Metsera Price Performance

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.